NCT00465634

Brief Summary

To assess the role of uterine artery and maternal serum leptin and lipids and their combination in screening for pre-eclampsia and small-for-gestational-age (SGA) fetuses at 20-24 weeks of gestation

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
235

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2003

Completed
4 years until next milestone

First Submitted

Initial submission to the registry

April 24, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 25, 2007

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2007

Completed
Last Updated

August 9, 2013

Status Verified

August 1, 2013

Enrollment Period

4.1 years

First QC Date

April 24, 2007

Last Update Submit

August 6, 2013

Conditions

Keywords

Screeninguterine artery DopplerHELLP syndromeabruption

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

women at increased risk of pre-eclampsia (PE) and intrauterine growth restriction (IUGR)

You may qualify if:

  • Chronic hypertension under medication
  • Diabetes
  • Thrombophilia
  • Previous history of pre-eclampsia
  • Previous history of unexplained stillbirth
  • Previous history of placental abruption
  • Previous history of SGA (\< 10th centile)
  • History of pre-eclampsia or chronic hypertension before 45 years in the mother or a sister
  • Obesity (BMI\>30)
  • Nulliparous after 40 years
  • Assisted conception with donor

You may not qualify if:

  • Multiple pregnancy
  • Complicated pregnancy with a high probability of required fetal extraction before term
  • Pregnancy requiring termination
  • Unability to understand the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Olympe de Gouges Women Health Centre, Bretonneau University Hospital

Tours, 37044, France

Location

Related Publications (4)

  • Papageorghiou AT, Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol. 2007 Apr;19(2):103-9. doi: 10.1097/GCO.0b013e32809bd964.

    PMID: 17353676BACKGROUND
  • Guven MA, Ertas IE, Kilinc M, Coskun A, Ekerbicer H. Combining mid-trimester maternal plasma homocysteine with uterine artery doppler velocimetry: is it useful? Arch Gynecol Obstet. 2007 Jun;275(6):439-43. doi: 10.1007/s00404-006-0281-5. Epub 2006 Nov 17.

    PMID: 17111155BACKGROUND
  • Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet Gynecol. 2006 Jun;27(6):658-63. doi: 10.1002/uog.2676.

    PMID: 16493628BACKGROUND
  • Tommaselli GA, Pighetti M, Nasti A, D'Elia A, Guida M, Di Carlo C, Bifulco G, Nappi C. Serum leptin levels and uterine Doppler flow velocimetry at 20 weeks' gestation as markers for the development of pre-eclampsia. Gynecol Endocrinol. 2004 Sep;19(3):160-5. doi: 10.1080/09513590400007267.

    PMID: 15697078BACKGROUND

MeSH Terms

Conditions

Pre-EclampsiaFetal Growth RetardationPlacental InsufficiencyHELLP Syndrome

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesFetal DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGrowth DisordersPathologic ProcessesPathological Conditions, Signs and SymptomsPlacenta Diseases

Study Officials

  • Franck Perrotin, MD-PhD

    Tours University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 24, 2007

First Posted

April 25, 2007

Study Start

May 1, 2003

Primary Completion

June 1, 2007

Study Completion

June 1, 2007

Last Updated

August 9, 2013

Record last verified: 2013-08

Locations